Alzamend Neuro (ALZN) vs Creative Medical Technology (CELZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Creative Medical Technology is the larger company by market cap ($6.5 million vs $6.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | CELZ |
|---|---|---|
| Share price | $1.34 | $0.8604 |
| Market cap | $6.47M | $6.53M |
| 1-day change | -2.19% | -2.45% |
| EPS (TTM) | $-2.30 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $6.25 |
| 52-week low | $0.84 | $0.62 |
| Distance from 52-week high | -50.00% | -86.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +1840.30% | +2224.50% |
| Average volume | 88.67K | 6.77M |
| Shares outstanding | 4.83M | 7.59M |
| Employees | 4 | 4 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Healthcare · Biotechnology · 4 employees
About Creative Medical Technology
CELZ stock →Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
Healthcare · Biotechnology · 4 employees
ALZN vs CELZ FAQ
Which is bigger, Alzamend Neuro or Creative Medical Technology?
Creative Medical Technology (CELZ) is larger, with a market capitalization of $6.53M compared with $6.47M for Alzamend Neuro (ALZN).
Are Alzamend Neuro and Creative Medical Technology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.